Common Contracts

Licensing and option agreement for iSONEP for wet age-related macular degeneration

License and Development Agreement • February 2nd, 2022 • New York

• Contract Type
  License and Development Agreement
• Filed
  February 2nd, 2022
• Jurisdiction
  New York

Lpath has entered into an agreement providing Pfizer with an exclusive option for a worldwide license to develop and commercialize iSONEPTM for the treatment of wet age-related macular degeneration (wet AMD) and other ophthalmology disorders.

OPTION, LICENSE AND DEVELOPMENT AGREEMENT by and between PFIZER INC. and LPATH, INC.

License and Development Agreement • March 23rd, 2011 • Lpath, Inc • Biological products, (no disgnostic substances) • New York

• Contract Type
  License and Development Agreement
• Filed
  March 23rd, 2011
• Company
  Lpath, Inc
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

*** Certain confidential portions of this Exhibit were omitted by means of blackout of the text (the “Mark”). This Exhibit has been filed separately with the Secretary of the Commission without the Mark pursuant to the Company’s Application Requesting Confidential Treatment under Rule 24b-2 under the 1934 Act.